In addition to a busy clinical practice, Dr. Kirsch is the President and Chief Executive Officer at ClearifiRx.com. He has interests in therapeutic drug development and medical innovation. In partnership with the Mayo Clinic, he filed to patent a novel topical composition for the treatment of melasma. He also received a grant from the Mayo Clinic to complete an investigator-initiated pilot study of this formulation.
Dr. Kirsch was previously an Assistant Clinical Professor of Dermatology at the University of Colorado and Medical Director and Vice President of Clinical Development at Brickell Biotech, Inc. At Brickell, Dr. Kirsch provided leadership and strategic direction for the clinical science team. In his role, he had primary responsibility for overseeing development programs from late preclinical to registration Phase 3 randomized studies. Dr. Kirsch has been published in the Journal of the American Medical Association, Journal of the American Academy of Dermatology, Journal of Drugs in Dermatology, Journal of Clinical and Aesthetic Dermatology, Dermatology Times, The Journal of Investigative Dermatology, The Journal of Cancer Immunology Research, The Canadian Journal of Neurological Sciences, Reason, The Wall Street Journal, The Toronto Star, The Providence Journal, and The Jacksonville Times-Union.